IMMUNOGENIC PHARMACEUTICALS

摘要

There are disclosed pharmaceuticals which comprise either part or all of a polypeptide or a nucleotide sequence coding for said part or all of a polypeptide which polypeptide is substantially homologous to a mutant protein produced in consequence of its mutation in a gene sequence which shifts translation from the gene sequence out of the list reading enzyme into either the second or third reading frames downstream of the mutation and which said part or all of a polypeptide is able to involve an immune response against the mutant protein.